Biogen Inc. announced the European Commission has authorized SKYCLARYS® (omaveloxolone) for the treatment of Friedreich’s Ataxia in adults and adolescents aged 16 years and older. SKYCLARYS is the first treatment approved within the European Union for this rare, genetic, progressive neurodegenerative disease.

Read More Here